The company said, “For fiscal year 2025, the Company expects combined revenue in the range of $165 million to $175 million. Revenue from continuing operations is expected in the range of $78 million to $83 million. This combined outlook continues to assume a high single-digit millions decline in our Americas academic revenue due to anticipated NIH funding pressures, with a more pronounced impact on our continuing operations. It also assumes no expected effect from U.S. export controls and limited impact from tariffs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LAB:
- LAB Upcoming Earnings Report: What to Expect?
- Standard BioTools, Precision Health, Singapore launch proteomic collaboration
- Standard BioTools Approves Stock Awards for Executives
- Standard BioTools Sells Subsidiaries to Illumina
- U.S. strikes Iran nuclear sites, Novo terminates Hims & Hers deal: Morning Buzz